PURPOSE: To investigate the hypothesis that faster drug absorption from a new paracetamol formulation containing sodium bicarbonate compared to that from a conventional formulation results from a combination of enhanced gastric emptying and disintegration/dissolution. METHODS: Each formulation was administered in both fasted and fed states to 12 healthy volunteers. Gastric emptying and disintegration times were assessed by gamma scintigraphy, and serum paracetamol concentrations were determined by HPLC. RESULTS: The mean time to complete disintegration of the new tablets was faster than that for conventional tablets in both fasted (10.2 min vs. 22.5 min) and fed (14.3 min vs. 46.4 min) states, although this difference was statistically significant in the fed state only (p = 0.0053). Mean gastric emptying times for the new tablets, as measured by t50 and t90, were also faster than those for conventional tablets in both fasted (t50 = 22.4 min vs. 47.5 min, t90 = 30.9 min vs. 64.1 min) and fed (t50 = 76.9 min vs. 106.4 min, t90 = 152.7 min vs. 155.5 min) states, although these differences were not statistically significant. Two subjects showed dramatically retarded gastric emptying of the new tablets in the fasted state: if these atypical data are excluded, the differences in both t50 and t90 in the fasted state are significant (p = 0.0110 and 0.0035, respectively). Rate of paracetamol absorption reflected the gastric emptying profiles as shown by significant correlation of emptying times with partial AUC. CONCLUSIONS: It would seem that a combination of faster disintegration and gastric emptying of the new tablets is responsible for the faster rate of absorption of paracetamol from PA compared to P observed in both this study and in previous studies. The differences in gastric emptying are more pronounced in the fasted state, and the differences in disintegration are more pronounced in the fed state.
RCT Entities:
PURPOSE: To investigate the hypothesis that faster drug absorption from a new paracetamol formulation containing sodium bicarbonate compared to that from a conventional formulation results from a combination of enhanced gastric emptying and disintegration/dissolution. METHODS: Each formulation was administered in both fasted and fed states to 12 healthy volunteers. Gastric emptying and disintegration times were assessed by gamma scintigraphy, and serum paracetamol concentrations were determined by HPLC. RESULTS: The mean time to complete disintegration of the new tablets was faster than that for conventional tablets in both fasted (10.2 min vs. 22.5 min) and fed (14.3 min vs. 46.4 min) states, although this difference was statistically significant in the fed state only (p = 0.0053). Mean gastric emptying times for the new tablets, as measured by t50 and t90, were also faster than those for conventional tablets in both fasted (t50 = 22.4 min vs. 47.5 min, t90 = 30.9 min vs. 64.1 min) and fed (t50 = 76.9 min vs. 106.4 min, t90 = 152.7 min vs. 155.5 min) states, although these differences were not statistically significant. Two subjects showed dramatically retarded gastric emptying of the new tablets in the fasted state: if these atypical data are excluded, the differences in both t50 and t90 in the fasted state are significant (p = 0.0110 and 0.0035, respectively). Rate of paracetamol absorption reflected the gastric emptying profiles as shown by significant correlation of emptying times with partial AUC. CONCLUSIONS: It would seem that a combination of faster disintegration and gastric emptying of the new tablets is responsible for the faster rate of absorption of paracetamol from PA compared to P observed in both this study and in previous studies. The differences in gastric emptying are more pronounced in the fasted state, and the differences in disintegration are more pronounced in the fed state.
Authors: A Rostami-Hodjegan; M R Shiran; G T Tucker; B R Conway; W J Irwin; L R Shaw; T J Grattan Journal: Drug Dev Ind Pharm Date: 2002-05 Impact factor: 3.225
Authors: A Rostami-Hodjegan; M R Shiran; R Ayesh; T J Grattan; I Burnett; A Darby-Dowman; G T Tucker Journal: Drug Dev Ind Pharm Date: 2002-05 Impact factor: 3.225
Authors: G Paintaud; P Thibault; P E Queneau; J Magnette; M Bérard; L Rumbach; P R Bechtel; P Carayon Journal: Eur J Clin Pharmacol Date: 1998-01 Impact factor: 2.953
Authors: L C Knight; H P Parkman; K L Brown; M A Miller; D M Trate; A H Maurer; R S Fisher Journal: Am J Gastroenterol Date: 1997-06 Impact factor: 10.864
Authors: A Wald; D H Van Thiel; L Hoechstetter; J S Gavaler; K M Egler; R Verm; L Scott; R Lester Journal: Gastroenterology Date: 1981-06 Impact factor: 22.682
Authors: Dimitrios Psachoulias; Maria Vertzoni; James Butler; David Busby; Moira Symillides; Jennifer Dressman; Christos Reppas Journal: Pharm Res Date: 2012-08-14 Impact factor: 4.200
Authors: Christos Reppas; Horst-Dieter Friedel; Amy R Barker; Lucinda F Buhse; Todd L Cecil; Susanne Keitel; Johannes Kraemer; J Michael Morris; Vinod P Shah; Mary P Stickelmeyer; Chikako Yomota; Cynthia K Brown Journal: Pharm Res Date: 2014-03-19 Impact factor: 4.200